Homology Medicines Inc. (FIXX)
Homology Medicines Statistics
Share Statistics
Homology Medicines has 3.23M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 3.23M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.04M |
| Failed to Deliver (FTD) Shares | 50 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.03 and the forward PE ratio is null. Homology Medicines's PEG ratio is 0.
| PE Ratio | -0.03 |
| Forward PE | n/a |
| PS Ratio | 3.04 |
| Forward PS | null |
| PB Ratio | 0.05 |
| P/FCF Ratio | -0.04 |
| PEG Ratio | 0 |
Enterprise Valuation
Homology Medicines has an Enterprise Value (EV) of -34.43M.
| EV / Sales | -29.79 |
| EV / EBITDA | 0.38 |
| EV / EBIT | 0.36 |
| EV / FCF | 0.36 |
Financial Position
The company has a current ratio of 7.25, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.25 |
| Quick Ratio | 7.25 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -154.76% and Return on Invested Capital is -160.78%.
| Return on Equity | -154.76% |
| Return on Assets | -36.9% |
| Return on Invested Capital | -160.78% |
| Revenue Per Employee | $165.14K |
| Profits Per Employee | $-16.14M |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 25.88M |
| Effective Tax Rate | -29.72% |
Stock Price Statistics
The stock price has increased by -0.5% in the last 52 weeks. The beta is -0.11, so Homology Medicines's price volatility has been lower than the market average.
| Beta | -0.11 |
| 52-Week Price Change | -0.5% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 65.97 |
| Average Volume (20 Days) | 29.54K |
Income Statement
In the last 12 months, Homology Medicines had revenue of 1.16M and earned -112.96M in profits. Earnings per share was -351.57.
| Revenue | 1.16M |
| Gross Profit | 578K |
| Operating Income | -92.1M |
| Net Income | -112.96M |
| EBITDA | -91.52M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -351.57 |
Balance Sheet
The company has 39.27M in cash and 1.32M in debt, giving a net cash position of 37.95M.
| Cash & Cash Equivalents | 39.27M |
| Total Debt | 1.32M |
| Net Cash | 37.95M |
| Retained Earnings | -542.1M |
| Total Assets | 152.33M |
| Working Capital | 105.09M |
Cash Flow
In the last 12 months, operating cash flow was -96.23M and capital expenditures -228K, giving a free cash flow of -96.46M.
| Operating Cash Flow | -96.23M |
| Capital Expenditures | -228K |
| Free Cash Flow | -96.46M |
| FCF Per Share | -300.21 |
Margins
Gross margin is 50%, with operating and profit margins of -7967.3% and -9771.71%.
| Gross Margin | 50% |
| Operating Margin | -7967.3% |
| Pretax Margin | -7532.87% |
| Profit Margin | -9771.71% |
| EBITDA Margin | -7917.3% |
| EBIT Margin | -7967.3% |
| FCF Margin | -8344.12% |
Dividends & Yields
FIXX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3213.62% |
| FCF Yield | -2744.13% |
Analyst Forecast
Currently there are no analyst rating for FIXX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 25, 2024. It was a backward split with a ratio of 1:18.
| Last Split Date | Mar 25, 2024 |
| Split Type | backward |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | -2.25 |
| Piotroski F-Score | 1 |